Jakeman, Bernadette; Scherrer, Alexandra U; Darling, Katharine E A; Damas, Jose; Bieler-Aeschlimann, Melanie; Hasse, Barbara; Schlosser, Ladina; Hachfeld, Anna; Gutbrod, Klemens; Tarr, Philip E; Calmy, Alexandra; Assal, Frederic; Kunze, Ursula; Stoeckle, Marcel; Schmid, Patrick; Toller, Gianina; Rossi, Stefania; di Benedetto, Caroline; du Pasquier, Renaud; Cavassini, Matthias; ... (2022). Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 9(9), ofac457. Oxford University Press 10.1093/ofid/ofac457
|
Text
ofac457.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (576kB) | Preview |
Background
We previously showed that anticholinergic (ACH) medications contribute to self-reported neurocognitive impairment (NCI) in elderly people with human immunodeficiency virus (PWH). The current cross-sectional study further evaluated the effect of ACH and sedative drugs on neurocognitive function in PWH who underwent comprehensive neuropsychological evaluation.
Methods
A medication review was performed in PWH enrolled in the prospective Neurocognitive Assessment in Metabolic and Aging Cohort within the Swiss HIV Cohort Study. Neurocognitive functions were analyzed in 5 domains (motor skills, speed of information, attention/working memory, executive functions, and verbal learning memory). The effect of ACH and sedative medications on neurocognitive functioning was evaluated using linear regression models for the continuous (mean z-score) outcome and multivariable logistic regression models for the binary (presence/absence) outcome.
Results
A total of 963 PWH (80% male, 92% Caucasian, 96% virologically suppressed, median age 52) were included. Fourteen percent of participants were prescribed ≥1 ACH medication and 9% were prescribed ≥1 sedative medication. Overall, 40% of participants had NCI. Sedative medication use was associated with impaired attention/verbal learning and ACH medication use with motor skills deficits both in the continuous (mean z-score difference -0.26 to -0.14, P < .001 and P = .06) and binary (odds ratio [OR], ≥1.67; P < .05) models. Their combined use was associated with deficits in overall neurocognitive functions in both models (mean z-score difference -0.12, P = .002 and OR = 1.54, P = .03). These associations were unchanged in a subgroup analysis of participants without depression (n = 824).
Conclusions
Anticholinergic and sedative medications contribute to NCI. Clinicians need to consider these drugs when assessing NCI in PWH.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Hachfeld, Anna, Gutbrod, Klemens |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2328-8957 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
26 Sep 2022 14:35 |
Last Modified: |
05 Dec 2022 16:25 |
Publisher DOI: |
10.1093/ofid/ofac457 |
PubMed ID: |
36147598 |
Uncontrolled Keywords: |
HIV anticholinergic medication neuro-HIV neurocognitive impairment sedative medication |
BORIS DOI: |
10.48350/173226 |
URI: |
https://boris.unibe.ch/id/eprint/173226 |